Wrapper or Moat? The Macroeconomic Re-Correction and the Rise of Health Tech 2.0

The healthcare technology mergers and acquisitions landscape has transitioned into a regime of industrial maturity, moving decisively past the speculative pricing cycles of the post-pandemic era. During the height of the market peak, high-growth digital health platforms were valued primarily on projected revenue expansion, frequently disregarding long-term margin profiles or underlying product defensibility. This pricing paradigm has been replaced by a rigorous valuation discipline that penalises standalone applications while heavily rewarding integrated, operationally defensive enterprise systems.
  
This macroeconomic correction is clearly illustrated by the overall market transaction values and volumes. In 2025, global health industries M&A values rose by 46%, even as transaction volumes declined by 5%. This divergence represents a dramatic concentration of capital into high-quality, large scale assets, highlighted by 11 mega deals that closed during the year. 
  
Furthermore, roughly 70% of total transaction value in 2025 originated from fewer than ten large deals, showcasing a persistent capital clustering at the top end of the market.
  
Underpinning this structural shift is the performance of the "Health Tech 2.0" cohort. This group, which includes companies like Waystar, Tempus AI, Hinge Health, Omada Health, Caris Life Sciences and HeartFlow, represents platforms that combine sustainable, high-velocity growth with clear operating leverage and robust data assets.

Strategic Conclusions and Outlook
  
The repricing of HealthTech M&A has established a clear division between shallow software wrappers and defensible clinical operating systems. Standalone point solutions that increase administrative complexity face continuing valuation pressure. Conversely, integrated, EHR-native platforms that automate workflows, improve margins, and maintain strong compliance moats command significant premiums.
  
For digital health founders, long-term value creation depends on clinical validation, regulatory readiness, and moving away from single-feature software models toward integrated enterprise solutions. 
  
For private equity and strategic buyers, success in this market requires executing deep, clinical due diligence, structuring performance-linked earn outs, and prioritising platforms that sit directly within core clinical and financial workflows.

Read the full article here https://www.healthcare.digital/single-post/wrapper-or-moat-how-ai-is-re-pricing-healthtech-m-a